A year ago CV Sciences was a standout in a hot market for cannabis stocks. Between March and August 2018 the shares increased nearly 20 fold, reaching $8.14. Since that time, things have been different. From last November (about the low point for cannabis stocks), CVSI shareholders have lost nearly 30 percent.
Full Answer
Is CV Sciences efficiently growing its dividend?
CV Sciences does not have a long track record of dividend growth. In the past three months, CV Sciences insiders have not sold or bought any company stock. Only 6.80% of the stock of CV Sciences is held by insiders. Only 0.02% of the stock of CV Sciences is held by institutions.
Should you hold CV Sciences (cvsi) stock?
The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares. View analyst ratings for CV Sciences or view top-rated stocks.
What are Wall Street's price targets for CV Sciences'stock?
3 Wall Street analysts have issued 12 month price objectives for CV Sciences' shares. Their predictions range from $5.00 to $9.00. On average, they anticipate CV Sciences' stock price to reach $7.33 in the next year.
Who is the founder of CV Sciences?
The company was founded by H. J. Cole, Michael J. Mona, Jr. and Michael J. Mona III on December 9, 2010 and is headquartered in San Diego, CA. Will CV Sciences, Inc. (CVSI) Report Negative Q3 Earnings?
Why is CV Sciences stock dropping?
Declining revenues, lower gross margins and being short on cash is going to pressure the company's stock; CV Sciences will have to raise capital as they are running out of cash.
Should I buy CV Sciences stock?
Should I buy or sell CV Sciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CV Sciences stock.
Is CVSI a buy or sell?
The median P/B ratio for stocks in the S&P is just over 3....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Should I buy or sell CV Sciences stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings...
What is CV Sciences' stock price forecast for 2022?
2 brokerages have issued 1-year price targets for CV Sciences' stock. Their CVSI stock forecasts range from $0.17 to $0.17. On average, they antici...
How has CV Sciences' stock performed in 2022?
CV Sciences' stock was trading at $0.12 at the start of the year. Since then, CVSI shares have decreased by 62.5% and is now trading at $0.0450. V...
How were CV Sciences' earnings last quarter?
CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings results on Monday, May, 16th. The company reported ($0.02) EPS for the quarter, meet...
Who are CV Sciences' key executives?
CV Sciences' management team includes the following people: Mr. Joseph D. Dowling , CEO, Sec. & Director (Age 65, Pay $418.52k) Mr. Joerg Grasse...
Who are some of CV Sciences' key competitors?
Some companies that are related to CV Sciences include RegeneRx Biopharmaceuticals (RGRX) , Lotus Pharmaceuticals (LTUS) , Emerald Bioscience (E...
What other stocks do shareholders of CV Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include (CGC) , Aurora Cannabi...
What is CV Sciences' stock symbol?
CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."
How do I buy shares of CV Sciences?
Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
About CV Sciences
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand.
Headlines
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock.
Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing
CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Will CV Sciences, Inc. (CVSI) Report Negative Q3 Earnings? What You Should Know
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know
CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What is CV Sciences?
CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Where is CV Sciences located?
and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California. More... Sector.
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI Massachusetts cannabis prices continue to fall Kentucky GOP Sen. Damon Thayer: "Medical cannabis is a slippery slope for recreational marijuana.”
The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
Below is a recap of the main news related to the cannabis industry and markets for the week of November 15, 2021. Contents
